InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.083

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 Noxopharm March 2020 Quarterly Report & Appendix 4C 30 Apr 2020 4:22PM $0.210 $0.083 fallen by 60.48%
$26 Abscopal Responses Achieved in Prostate Cancer 30 Apr 2020 10:10AM $0.205 $0.083 fallen by 59.51%
$26 Pipeline Expands With Potential New Brain Cancer Treatment 23 Apr 2020 8:37AM $0.180 $0.083 fallen by 53.89%
$26 Approval to be sought for COVID-19 Clinical Study in U.S. 21 Apr 2020 8:17AM $0.170 $0.083 fallen by 51.18%
$26 Receipt of cash payment for collateral shares 20 Apr 2020 4:52PM $0.170 $0.083 fallen by 51.18%
$26 Noxopharm trial data to be presented at ASCO 2020 7 Apr 2020 8:20AM $0.215 $0.083 fallen by 61.40%
$26 Updated Noxopharm Virtual Roadshow Corporate Presentation 2 Apr 2020 8:43AM $0.270 $0.083 fallen by 69.26%
$26 Noxopharm Investigating Potential COVID-19 Treatment 1 Apr 2020 10:11AM $0.140 $0.083 fallen by 40.71%
$26 Noxopharm Virtual Roadshow Corporate Presentation 31 Mar 2020 10:07AM $0.120 $0.083 fallen by 30.83%
$26 Initial Director's Interest Notice 26 Mar 2020 9:55AM $0.110 $0.083 fallen by 24.55%
$26 Appointment of New Board Member 26 Mar 2020 9:54AM $0.110 $0.083 fallen by 24.55%
$26 Veyonda Awarded First Allowed Patent Application 17 Mar 2020 8:22AM $0.155 $0.083 fallen by 46.45%
$26 Veyonda Clinical Program Update and Guidance 13 Mar 2020 8:13AM $0.165 $0.083 fallen by 49.70%
$26 LuPIN Prostate Cancer Trial Fully Recruited 3 Mar 2020 8:21AM $0.240 $0.083 fallen by 65.42%
$26 Noxopharm Corporate Presentation February 2020 27 Feb 2020 8:28AM $0.240 $0.083 fallen by 65.42%
$26 Half Year Accounts and Chairman Letter 25 Feb 2020 1:24PM $0.230 $0.083 fallen by 63.91%
$26 Section 708 Certificate 21 Feb 2020 2:02PM $0.295 $0.083 fallen by 71.86%
$26 Appendix 2A 21 Feb 2020 2:00PM $0.295 $0.083 fallen by 71.86%
$26 FDA grants IND approval to Veyonda 21 Feb 2020 9:36AM $0.235 $0.083 fallen by 64.68%
$26 Termination of Convertible Loan 18 Feb 2020 1:14PM $0.280 $0.083 fallen by 70.36%
$26 Section 708 Certificate 18 Feb 2020 1:11PM $0.280 $0.083 fallen by 70.36%
$26 Appendix 2A 18 Feb 2020 1:08PM $0.280 $0.083 fallen by 70.36%
$26 Noxopharm Alliance With GenesisCare 18 Feb 2020 8:59AM $0.270 $0.083 fallen by 69.26%
$26 Proposed issue of Securities - NOX 14 Feb 2020 10:10AM $0.225 $0.083 fallen by 63.11%
$26 $8.1M Financing & Re-Set of Capital Structure 14 Feb 2020 10:09AM $0.225 $0.083 fallen by 63.11%

426 - 450 of 794 results

Page 18 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.